Pegfilgrastim Biosimilars Market Report 2026

Pegfilgrastim Biosimilars Market Overview

• Pegfilgrastim Biosimilars market size has reached to $1.92 billion in 2025 • Expected to grow to $2.65 billion in 2030 at a compound annual growth rate (CAGR) of 6.7% • Growth Driver: Government Initiatives Drive Growth In Pegfilgrastim Biosimilars Market • Market Trend: High Quality Biosimilar For Providing Better Alternative • North America was the largest region in 2025 and Middle East is the fastest growing region.

What Is Covered Under Pegfilgrastim Biosimilars Market?

Pegfilgrastim biosimilars refer to a biosimilar that is intended to be used in conjunction with supportive care for people with non-myeloid cancer. It can help prevent or treat infections brought on by myelosuppressive chemotherapy by promoting the formation of certain white blood cells. The different applications of pegfilgrastim biosimilars are chemotherapy treatment, transplantation, and others. Chemotherapy is a cancer treatment that involves the administration of one or more anti-cancer medications as part of a defined protocol. The various distribution channels include hospital pharmacies, retail pharmacies, and mail-order pharmacies.

What Is The Pegfilgrastim Biosimilars Market Growth Forecast?

The pegfilgrastim biosimilars market size is expected to see strong growth in the next few years. It will grow to $2.65 billion in 2030 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to launch of new biosimilars, increasing adoption in supportive oncology care, expansion of hospital and retail pharmacy networks, government incentives for biosimilar usage, rising investments in stem cell transplantation therapies. Major trends in the forecast period include rising adoption of pegfilgrastim biosimilars in supportive cancer care, expansion of hospital and retail pharmacy distribution channels, increasing focus on reducing chemotherapy-induced neutropenia, growth in hematopoietic and peripheral blood stem cell transplantation applications, rising investments in treatment of chronic and severe congenital neutropenia.

Global Pegfilgrastim Biosimilars Market Segmentation

1) By Application: Chemotherapy Treatment, Transplantation, Other Applications 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Mail-Order Pharmacies 3) By Route of Administration: Prefilled Syringes (PFS), On-body Injectors (OBI), Other Routes Subsegments: 1) By Chemotherapy Treatment: Supportive Care for Cancer Patients, Reduction of Chemotherapy-Induced Neutropenia 2) By Transplantation: Hematopoietic Stem Cell Transplantation, Peripheral Blood Stem Cell Transplantation 3) By Other Applications: Treatment of Chronic Neutropenia, Treatment of Severe Congenital Neutropenia

What Are The Drivers Of The Pegfilgrastim Biosimilars Market?

Government initiatives for the development of biosimilars are expected to drive the pegfilgrastim biosimilars market. Governments worldwide are focusing on the development of biosimilars due to their cost-effective nature. The US Food and Drug Administration (FDA) launched a Biosimilar Action Plan, to increase treatment options. The Australian government is committed to the Biosimilar Awareness Initiative, and they improved their commitment by supporting the Generic and Biosimilar Medicines Association through a grant of $5 million to accept increased general biosimilar education and activities that promote the suitable dispensing, prescription, and use of biosimilar medicines. Hence, the government initiatives for the development of biosimilars aid in the increased production and awareness that, in turn, support the growth of the pegfilgrastim biosimilars industry. The increased incidence of cancer is expected to propel the pegfilgrastim biosimilars market going forward. Cancer refers to a group of diseases characterized by the uncontrolled growth and spread of abnormal cells. The increasing cancer prevalence is due to aging population, as advanced age is the most significant risk factor for developing most types of cancer, with the majority of cases occurring in individuals over 65 years old. Pegfilgrastim biosimilars are used to reduce the risk of infection in cancer patients undergoing chemotherapy by stimulating white blood cell production. For instance, in October 2025, according to National Health Service (NHS), a UK-based government health agency, there were 354,820 new cancer diagnoses in 2023, an average of 972 per day, which is 8,605 more than in 2022. Therefore, the increased incidence of cancer is driving the pegfilgrastim biosimilars industry.

Key Players In The Global Pegfilgrastim Biosimilars Market

Major companies operating in the pegfilgrastim biosimilars market are Amgen, Mylan N.V., Sandoz (a Novartis division), Teva Pharmaceutical Industries Ltd., Biocon, Pfizer, Celltrion Healthcare, Coherus BioSciences, Gedeon Richter, Fresenius Kabi, Hetero Labs, Intas Pharmaceuticals, LG Chem, Merck KGaA, Zydus Cadila, Aurobindo Pharma, Apotex Inc., Dr. Reddy's Laboratories, Stada Arzneimittel AG, Shanghai Henlius Biotech, Alvotech, EirGenix, Kye Pharmaceuticals, CinnaGen, Boryung Pharmaceutical, Sinopharm

Global Pegfilgrastim Biosimilars Market Trends and Insights

Major companies operating in the pegfilgrastim biosimilars market are focusing on technological innovation in biopharmaceuticals, such as high-quality biosimilars to provide safe, effective, and accessible alternatives to original biologic therapies for cancer patients. High-quality biosimilars refer to biologic drugs that closely match the reference product in structure, function, safety, and efficacy. For instance, in February 2023, Fresenius Kabi, a Germany-based healthcare company specializing in pharmaceuticals and medical technologies, launched Stimufend, its first pegfilgrastim biosimilar in the U.S. Stimufend prevents and treats chemotherapy-induced neutropenia and comes as a 6 mg/0.6 mL solution in a single-use pre-filled syringe with a built-in needle guard. By combining advanced biosimilar development and user-friendly delivery, Stimufend represents a technological advancement in making high-quality biologic therapies more accessible.

What Are Latest Mergers And Acquisitions In The Pegfilgrastim Biosimilars Market?

In August 2025, Intas Pharmaceuticals Ltd., an India-based biotechnology company, acquired the UDENYCA from Coherus BioSciences, Inc. for an undisclosed amount. With this acquisition, Intas Pharmaceuticals and Accord BioPharma aim to strengthen their position as a global leader in pegfilgrastim, expand their FDA-approved biosimilar portfolio, and enhance patient access to high-quality, flexible treatment options for reducing the risk of infection in cancer patients. Coherus BioSciences Inc. is a US-based, commercial-stage biopharmaceutical company, focused on both biosimilars and innovative immuno-oncology therapies, with a team of industry veterans leveraging deep expertise in biologics development and commercialization.

Regional Insights

North America was the largest region in the pegfilgrastim biosimilars market in 2025. Middle East is expected to be the fastest growing region in the global pegfilgrastim biosimilars market share during the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Pegfilgrastim Biosimilars Market?

The pegfilgrastim biosimilars market consists of sales of fulphila, pelgraz, pelmeg, udenyca, ziextenzo, grasustek, fylnetra, and stimufend. Values in this market are ""factory gate values,"" that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Pegfilgrastim Biosimilars Market Report 2026?

The pegfilgrastim biosimilars market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the pegfilgrastim biosimilars industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.